Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer. [electronic resource]
Producer: 20151103ISSN:- 1548-8756
- Animals
- Antibodies -- adverse effects
- Antineoplastic Agents -- adverse effects
- Apoptosis -- drug effects
- B7-H1 Antigen -- antagonists & inhibitors
- CTLA-4 Antigen -- antagonists & inhibitors
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Humans
- Immunotherapy -- adverse effects
- Lung Neoplasms -- drug therapy
- Lymphocyte Activation -- drug effects
- Molecular Targeted Therapy -- adverse effects
- Programmed Cell Death 1 Receptor -- antagonists & inhibitors
- Risk Factors
- Signal Transduction -- drug effects
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review; Video-Audio Media
There are no comments on this title.
Log in to your account to post a comment.